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Abstract
Therapeutic targeting of host cell factors required for virus replication rather than of pathogen components opens new
perspectives to counteract virus infections. Anticipated advantages of this approach include a heightened barrier against
the development of viral resistance and a broadened pathogen target spectrum. Myxoviruses are predominantly associated
with acute disease and thus are particularly attractive for this approach since treatment time can be kept limited. To identify
inhibitor candidates, we have analyzed hit compounds that emerged from a large-scale high-throughput screen for their
ability to block replication of members of both the orthomyxovirus and paramyxovirus families. This has returned a
compound class with broad anti-viral activity including potent inhibition of different influenza virus and paramyxovirus
strains. After hit-to-lead chemistry, inhibitory concentrations are in the nanomolar range in the context of immortalized cell
lines and human PBMCs. The compound shows high metabolic stability when exposed to human S-9 hepatocyte subcellular
fractions. Antiviral activity is host-cell species specific and most pronounced in cells of higher mammalian origin, supporting
a host-cell target. While the compound induces a temporary cell cycle arrest, host mRNA and protein biosynthesis are
largely unaffected and treated cells maintain full metabolic activity. Viral replication is blocked at a post-entry step and
resembles the inhibition profile of a known inhibitor of viral RNA-dependent RNA-polymerase (RdRp) activity. Direct
assessment of RdRp activity in the presence of the reagent reveals strong inhibition both in the context of viral infection and
in reporter-based minireplicon assays. In toto, we have identified a compound class with broad viral target range that blocks
host factors required for viral RdRp activity. Viral adaptation attempts did not induce resistance after prolonged exposure, in
contrast to rapid adaptation to a pathogen-directed inhibitor of RdRp activity.
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Introduction
Myxoviruses are enveloped, negative-strand RNA viruses that
are transmitted through the respiratory route. The orthomyxovi-
rus family comprises five different genera of which the influenza
viruses are clinically most relevant. Of the paramyxoviridae,
respiratory syncytial virus (RSV), measles virus (MeV), mumps
virus (MuV), human parainfluenzaviruses (HPIV) and the recently
emerged, highly pathogenic zoonotic henipaviruses constitute
major human pathogens [1]. Although clinical complications
associated with some myxoviruses involve persistent infections, the
viruses predominantly induce acute respiratory or systemic disease.
Collectively, myxoviruses are responsible for the majority of
human morbidity and mortality due to viral respiratory illness
globally [2,3]. In particular, influenza virus is the leading cause of
morbidity and mortality from respiratory disease in North
America despite the existence of vaccine prophylaxis. This is due
to the fact that the vaccines currently in use reduce illness in
approximately 70% of healthy adults when homologous to the
prevalent circulating virus, but protection in the elderly reaches
only approximately 40%. Vaccine efficacy is reduced substantially
when the circulating strains differ from those constituting the
vaccine [2].
Despite extensive research and in contrast to, for instance, MeV
and MuV, no vaccines are currently available against several
major pathogens of the paramyxovirus family such as RSV or
different HPIVs. Infection with RSV is the leading cause of
pneumonia and bronchiolitis in infants, both associated with
significant mortality, while HPIV types 1 and 2 are the primary
cause of croup syndrome and can likewise result in serious lower
respiratory diseases such as pneumonia and bronchiolitis [4,5].
The availability of effective antiviral therapy for most clinically
significant myxovirus infections is limited. Licensed neuraminidase
inhibitors for influenza therapy, Zanamivir and Oseltamivir, show
efficacy when administered within a 48-hour window after the
onset of symptoms, but are increasingly compromised by pre-
existing or emerging viral resistance [6,7,8]. Ribavirin, although
approved for RSV treatment, shows limited utility due to efficacy
and toxicity issues [9]. The polyclonal immunoglobulin RSV-
IVIG [10] and the humanized monoclonal antibody Synagis [11]
provide RSV prophylaxis, but use is limited to high-risk pediatric
patients. Considering the high mutation rates seen in particular
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myxovirus inhibitors that circumvent the rapid development of
resistance is highly desirable.
Of the strategies conceivable towards this goal, targeting host
factors required for completion of the viral life cycle rather than
pathogen-encoded factors directly has received heightened interest
in recent years [14,15]. This approach is expected to establish a
significant barrier against spontaneous viral escape from inhibi-
tion, since individual viral mutations are less likely to compensate
for the loss of an essential host cofactor than to prevent high-
affinity binding of a conventional, pathogen-directed antiviral.
Given some degree of overlap of host cell pathways required for
successful replication of related viral pathogens, host-directed
antiviral approaches also have the potential to move beyond the
one-bug one-drug paradigm by broadening the pathogen target
range of a chemical scaffold.
Naturally, targeting host factors for antiviral therapy bears an
inherently higher potential for undesirable drug-induced side
effects than conventional pathogen-directed strategies. While the
approach is nevertheless under investigation for the treatment of
chronic viral infections such as HSV-1 and HIV-1 [16,17], an
application to the inhibition of infections by pathogens predom-
inantly associated with severe acute disease, such as most
members of the myxovirus families, is anticipated to render
drug-related side effects tolerable to some extent, since the
necessary treatment time and concomitant host exposure to the
drug remain limited. In the case of influenza infections, for
instance, typical neuraminidase inhibitor regimens consist of
twice daily administration for a five-day period for treatment, or a
10-day period for prophylaxis [18].
Relying on a broadened anti-myxovirus target spectrum as the
main selection criterion in secondary screening assays, we have
mined results of a recently completed high throughput chemical
library screen [19] to identify hit candidates with a possible host-
directed mechanism of action. This has yielded a compound class
with broad anti-viral activity, which was subjected to synthetic
scaffold optimization, quantification of active concentrations for a
select group of clinically relevant ortho- and paramyxovirus family
members, testing against a panel of exposed host cells of different
species origin, and characterization of the compound-induced
point-of-arrest in viral life cycle progression. Viral adaptation to
growth in the presence of inhibitor has been employed to compare
escape rates from inhibition by this new compound class with
those from a well-characterized, pathogen-directed antiviral.
Results
To identify small-molecule hit candidates that block the
myxovirus life cycle through a host-directed mechanism, we
analyzed the results of a high-throughput cell-based anti-MeV
screen of a 137,500-entry library of the NIH diversity set that we
recently reported [19]. The primary screening agent, serving as
the myxovirus representative, was the wild type MeV isolate MVi/
Alaska.USA/16.00 (MeV-Alaska). It was chosen based on its ease
of growth and readily quantifiable cytopathic effect in the
automated system [19,20]. In search of candidates with a host-
directed antiviral profile, we anticipated three distinct features of
desirable compounds: a) potent inhibition of virus replication at
the screening concentration (3.3 mM); b) a primary screening
score, representative of the selectivity index (CC50/EC50), close to
the cut-off value for hit candidates due to some anticipated host-
cell interference (=1.9); and c) a broadened viral target spectrum
in counterscreening assays that extends to other pathogens of the
myxovirus families.
Identification of a chemical scaffold with broad anti-viral
activity
When inhibition of paramyxovirus family members was
assessed, six compounds efficiently blocked the closely related
canine distemper virus (CDV) and the more distantly related
human parainfluenzavirus type 3 (HPIV3) in addition to MeV-
Alaska, while leaving cell metabolic activity essentially unaffected
[19]. Of these independent hits, three share a common molecular
scaffold ([19] and figure 1A). Since HTS scores of these analogs
best matched the target criteria and antiviral activity was highest
in this group [19], we subjected them to further characterization
and developmental efforts. Synthetic optimization and structural
confirmation of the scaffold returned a lead analog JMN3-003
(figures 1B and S1), which showed potent activity against MeV, a
selection of clinically significant members of the para- and
orthomyxovirus families, and, albeit to a lesser degree, represen-
tatives of positive strand RNA virus (sindbis virus of the
Alphaviridae) and DNA virus (vaccinia virus of the Poxviridae)
families (figure 1C, inhibitory concentrations for a larger panel of
myxovirus family members are summarized in table 1). As
observed for the primary hit compound, metabolic activity of
different established cell lines exposed to JMN3-003 was
unchanged at 75 mM, the highest assessable concentration based
on solubility of the substance in growth media (figure 1D and
table 1). Of different primary human cells examined, metabolic
activity was unaffected (PBMCs, smooth muscle cells) or only
slightly affected (bronchial epithelial cells) by the compound
(figure 1E). These data support potent anti-myxovirus activity of
the compound with active concentrations ranging from 10 to
80 nM depending on the target virus.
Antiviral activity of lead compound JMN3-003 is host cell-
specific
To further explore whether JMN3-003 meets the profile of a
host-directed antiviral, we examined whether the extent of
inhibition is determined by the species origin of the host cell used
for virus propagation. Based on its broad host cell range, inhibition
of influenza A/WSN replication was monitored. In addition to
higher mammalian (HT1080 (ATCC CCL-121), HeLa (ATCC
CCL-2), MDCK (ATCC CCL-34)) cell lines, cells of rodent (NIH-
3T3 (ATCC CRL-1658), MEL B16 (ATCC CRL-6322), BHK-21
(ATCC CCL-10), CHO (ATCC CCL-61)) and avian (DF-1
(ATCC CRL-12203)) origin were tested, which are all permissive
for influenza A/WSN infection (table 2). While inhibitory
concentrations obtained for all higher mammalian cell lines
examined were similar, A/WSN inhibition by JMN3-003 was
found inactive on some rodent cell lines and when virus was
propagated on murine or avian cells (table 2). However, inhibitory
activity extended fully to primary human PBMCs (figure 2). For
the latter, inhibition of MeV-Alaska was monitored due to efficient
growth of MeV isolates on PBMCs [21]. The host cell species
effect of antiviral activity of JMN3-003 is consistent with specific
targeting of cellular factors by the compound, while arguing
against docking to conserved viral factors or an undesirable
promiscuous, unspecific mode of activity.
JMN3-003 shows high metabolic stability in vitro
The central 2-thio-connector found in the chemical scaffold of
JMN3-003 may render the compound susceptible to rapid phase I
oxidation in vivo [22], thus possibly compromising its developmen-
tal potential. To test metabolic stability of the substance early in
development, we exposed JMN3-003 to human S-9 hepatocyte
subcellular fractions as an in vitro indicator for phase I metabolism.
Inhibitor of Myxovirus RdRp
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material remained intact, corresponding to an extrapolated half-
life of approximately 200 minutes (figure 3A). Unstable analogs of
JMN3-003, JMN5-165 and JMN5-166 (figure S1), returned half
lives of 38 and 5 minutes in this assay, respectively, confirming
metabolic competency of the S9 fractions used.
Assessment of JMN3-003 stability in human plasma in
comparison with unstable Procaine and stable Procainamide
Figure 1. Identification of a chemical scaffold with broad anti-myxovirus activity. Chemical structures of the identified scaffold (A) and the
current lead analog JMN3-003 (B). C) Dose-response curves for JMN3-003 and MeV-Alaska, MuV-South Africa, RSV Long, influenza A/WSN (H1N1),
sindbis virus and vaccinia virus. Titers of cell-associated progeny viruses were determined by TCID50 titration (MeV) or plaque assay (MuV, RSV, sindbis
virus, vaccinia virus). For influenza virus, genome copy numbers of released progeny particles were quantified through TaqMan RT-PCR. Titers of
released sindbis virus particles were determined by plaque assay. Values reflect averages of at least three experiments 6 SD, vaccinia virus titers were
determined in duplicate. D and E) Assessment of metabolic activity of cells after incubation of different established cell lines (D) or primary human
cells (E) in the presence of JMN3-003 for 24 hours. Results for human (HeLa, A549, HepG2), primate (Vero-Slam), and canine (MDCK) cell lines and
primary human cells (PBMC, smooth muscle, bronchial epithelial) are shown. Values reflect averages of four replicates 6 SD.
doi:10.1371/journal.pone.0020069.g001
Table 1. Active (EC50) and toxic (CC50, determined on Vero-Slam cells) concentrations of JMN3-003 against a selection of clinically
relevant para- and orthomyxovirus family members in comparison with active concentrations of AS-136A, a previously
characterized, MeV-specific inhibitor of the viral RdRp complex [20,36].
Compound Orthomyxoviridae
a Paramyxoviridae Toxicity
Influenza
A/WSN
Influenza
A/PR/8/34
SOI
Influenza
A/Texas
SOI Influenza
A/Mexico
RSV
b
(Long)
MuV
b
(S. Africa) HPIV3
b
MeV
c
(Alaska)
Metabolic
activity
EC50 [mM] CC50 [mM]
d
JMN3-003 0.0160.008 0.0160.001 0.0460.01 0.0160.003 0.0760.01 0.03360.031 0.0860.01 0.0360.02 .75
AS-136A none detected ND ND ND none detected none detected none detected 0.03
e (0.01–0.05) .75
aFor influenza virus titration, genome copy numbers of released progeny particles were quantified by TaqMan RT-PCR.
bTitered through plaque assaying.
cTitered by TCID50 titration.
dHighest concentration assessed 75 mM.
e95% confidence interval.
ND: not determined.
doi:10.1371/journal.pone.0020069.t001
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virtually unaffected after a 120-minute incubation period
(figure 3B). Taken together, these findings suggest desirable
metabolic stability for the JMN3-003 scaffold, recommending it
for further mechanistic characterization. The data are corrobo-
rated by the good metabolic stability reported for the structurally
similar compound RDEA-806 (figure S2), a non-nucleoside
inhibitor of HIV reverse transcriptase and clinical precedent
[24], which shares the 2-thio-connector of JMN3-003 but lacks
MeV inhibitory activity in our assays (data not shown).
Temporary arrest in cell cycle progression
Since direct cytotoxicity of JMN3-003 was low for all cell lines
examined, we next tested the effect of the substance on cell cycle
progression. Analysis of the DNA content of cells continuously
treated with JMN3-003 for 36 hours by flow cytometry revealed
accumulation of cells in a single population with 2N DNA content,
which closely resembled the profile of a reference cell population
exposed to hydroxyurea but markedly differed from the 4N DNA
content of nocodazole-treated cells (figure 4A). Nocodazole
interferes with microtubule polymerization [25], resulting in a
G2/M arrest, whereas hydroxyurea is thought to lead to an arrest in
the G1/S-phase through depletion of cellular dNTP pools [26,27].
To further explore the effect of JMN3-003 on cell cycle progression,
we monitored the phosphorylation status of the cdc2-cyclin B kinase
after exposure of cells to either the compound, hydroxyurea,
nocodazole,oralsterpaullone,ananomolarsmallmoleculeinhibitor
of cyclin-dependent kinases that reportedly induces a potent G1/S-
phase cell cycle arrest [28]. Pivotal in regulating the G2/M
transition, cdc2-cyclin B kinase is inactivated through phosphory-
lation during the G2-phase. Accumulation in its phosphorylated
form thus indicates a G1 arrest. As in hydroxyurea- and
alsterpaullone-treated controls, exposure of cells to JMN3-003
resulted in increased steady state levels of phosphorylated cdc2-
cyclin B kinase, supporting a G1-phase arrest (figure 4B).
To test whether this JMN3-003-induced arrest is permanent or
temporary, we next incubated cells in the presence of compound
or vehicle alone for 30 hours, followed by removal of the substance
and reseeding of cells at identical densities. Monitoring cell growth
over an additional 72-hour incubation period in the absence of
JMN3-003 revealed that proliferation rates resumed those of
untreated control cells after removal of the compound (figure 4C),
indicating reversibility of the growth arrest.
In contrast to members of the orthomyxovirus family,
paramyxovirus replication takes place in the cytosol and, thus, is
considered not to be immediately dependent on active cell
proliferation [1]. In fact, MeV itself has been shown to induce a
G1/S arrest in infected T lymphoyctes [29,30], confirming that
cell cycle progression is not required for virus replication. To
directly test whether the JMN3-003-mediated growth arrest per se is
causal for the antiviral effect of the compound, we generated
MeV-Alaska inhibition curves of JMN3-003 in comparison with
the cyclin-dependent kinase inhibitor alsterpaullone. Even at the
highest concentration assessed (50 mM), alsterpaullone caused only
a marginal reduction in MeV yields (figure 4D). These findings
indicate that the antiviral effect of JMN3-003 is based on an
upstream effect of the compound rather than being a consequence
of the cell cycle arrest itself.
Figure 2. The cellular target range of JMN3-003 extends to
primary human cells. Dose-response curves for MeV-Alaska grown in
the presence of JMN3-003 on human PBMCs originating from a mixed
pool of healthy donors. Vero-Slam cell-based inhibition curves are
shown for comparison. Values reflect averages of three replicates. EC50
concentrations 6 SD are derived from four-parameter non-linear
regression modeling.
doi:10.1371/journal.pone.0020069.g002
Table 2. Antiviral activity of JMN3-003 is host cell species-specific.
Host Cell Starting Titer
a EC50
b CC50
c
Influenza A/WSN yields
in controls
Inhibition of Influenza
A/WSN Metabolic Activity
Cell Line Origin [pfu/ml] [mM] [mM]
HT1080 Human 1.5610
6 0.0660.002 .75
HeLa Human 1.6610
3 0.0260.01 .75
MDCK Canine-dog 3.0610
7 0.0160.08 .75
NIH-3T3 Rodent-mouse 8.4610
5 .10 .75
MEL B16 Rodent-mouse 5.3610
5 .10 .75
BHK-21 Rodent-Syrian hamster 1.7610
7 0.0860.01 .75
CHO Rodent-Chinese hamster 1.5610
5 0.0760.01 .75
DF-1 Avian-chicken 1.3610
6 .10 .75
atiters of progeny virus grown on the different cell lines in the presence of vehicle (DMSO) only were determined through plaque assays on MDCK cells.
bEC50 concentrations were determined based on four parameter non-linear regression models generated for individual dose-response curves.
cHighest concentration assessed 75 mM.
Active concentrations (EC50) of JMN3-003 against influenza A/WSN propagated on a variety of different host cell lines.
doi:10.1371/journal.pone.0020069.t002
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unperturbed by JMN3-003
To explore whether growth arrest of treated cells coincides with
reduced host cell RNA synthesis or overall cell protein
biosynthesis, we next assessed the effect of JMN3-003 on host
mRNA and protein production. Relative levels of three signature
host mRNAs with short half lives, MCL1, ASB7 and MKP1
[31,32], were determined by real time PCR after incubation of
cells in the presence of different JMN3-003 concentrations ranging
from 0.01 to 10 mM. In all cases, mRNA levels of JMN3-003-
exposed cells were similar to those of the vehicle-treated
references, while exposure to Actinomycin D, which blocks
RNA synthesis through arrest of the transcription initiation
complex [33], resulted in a major reduction in relative mRNA
levels (figure 5A).
Immunodetection of cellular GAPDH and plasmid-encoded
MeV F protein under the control of the CMV promoter
demonstrated that productive transcription in the presence of
the compound furthermore coincides with uninterrupted transla-
tion and, in the case of F, co-translational insertion into the host
secretory system (figure 5B). Furthermore, equivalent levels of
proteolytically processed F1 material in JMN3-003 and vehicle-
exposed cells indicated that intracellular vesicular transport
remains intact in the presence of JMN3-003, since cleavage is
mediated by the cellular protease furin in a late-Golgi compart-
ment [1]. In contrast to host-encoded or transiently expressed
proteins, expression of virus-encoded proteins in the context of
paramyxovirus or orthomyxovirus infection was fully blocked by
100 nM JMN3-003 (figures 5C and D). Thus, these observations
demonstrate that the compound efficiently suppresses the
expression of virus-encoded proteins, but that this is not due to
general interference of the inhibitor with cellular mRNA synthesis
or translation. This phenotype suggests possible interference of
JMN3-003 with early steps of the viral life cycle, such as entry or
viral RdRp activity, as the basis for antiviral activity.
Inhibition of a post-entry step of the viral life cycle
To differentiate between those alternatives and identify the
point of arrest in the viral life cycle induced by JMN3-003, we first
examined whether the compound blocks membrane fusion and
thus viral entry. Expression of plasmid-encoded paramyxovirus
envelope glycoproteins in receptor-positive cells typically results in
extensive cell-to-cell fusion, the hallmark cytopathic effect
associated with most paramyxovirus infections in vitro [1].
Transient membrane fusion assays allow a quantitative assessment
of whether an inhibitor blocks viral entry or post-entry steps of the
viral life cycle [20,34]. When we examined MeV glycoprotein-
mediated cell-to-cell fusion microscopically (figure 6A) and in a
luciferase reporter-based quantitative cell-to-cell fusion assay
(figure 6B) in the presence of JMN3-003, we observed extensive
membrane fusion indistinguishable from that seen in vehicle-
treated controls, indicating that the compound does not act as an
entry inhibitor.
To determine whether JMN3-003 predisposes host cells against
viral infection by inducing an antiviral state, we pre-treated cells
with the compound, followed by wash-out of the substance and
virus infection after different time periods. Independent of
incubation time after removal of the compound, we could not
detect any substantial inhibitory effect in this set-up (figure 6C),
arguing against priming of the innate antiviral response by JMN3-
003. Likewise, preincubation of viral particles with JMN3-003
prior to removal of the article and infection lacked any appreciable
antiviral effect (figure 6D), excluding direct virucidal activity of the
substance.
When added in a time-of-addition experiment at distinct time
points post-infection in comparison with two previously charac-
terized, pathogen-targeted antivirals, the inhibition profile of
JMN3-003 was distinct from that of the entry inhibitor AS-48 [34]
but very closely resembled the profile of the AS-136A RdRp
blocker class ([20], figure 6E). Thus, these data point towards
inhibition of the viral RdRp activity by JMN3-003 as one possible
underlying mechanism for antiviral activity of the compound.
Host-directed inhibitor of viral RdRp activity
For myxovirus infection, the viral RdRp complex mediates both
genome transcription and replication to express viral proteins and
generate progeny genomes, respectively. Replication occurs
through generation of an antigenome of positive polarity, which
then serves as template for negative strand genome synthesis [1].
To directly test whether JMN3-003 affects viral RdRp activity in
the context of virus infection, we determined the copy numbers of
MeV-Alaska mRNA and antigenome in infected, compound-
treated cells relative to vehicle-treated controls by quantitative
RT-PCR. Presence of JMN3-003 caused a dose-dependent
reduction in viral RNA levels (figure 7A). At a concentration of
100 nM, for instance, we observed a .100-fold reduction of viral
Figure 3. The JMN3-003 scaffold is metabolically stable in vitro.A ) Incubation of the article with human liver S9 fractions for up to
60 minutes, followed by LC-MS/MS analysis of the material remaining. Two analogs of JMN3-003, JMN5-165 and JMN5-166 (figure S1), showed little
stability and are included for comparison. Values represent averages of 2 replicates, calculated half-lives (t1/2) are given in the figure captures. B)
Incubation of JMN3-003 for up to 120 minutes with human plasma derived from mixed, healthy donors, followed by LC-MS/MS quantification of the
material remaining. Unstable procaine and stable procainamide were examined equally for comparison. Values represent averages of three
experiments 6 SD.
doi:10.1371/journal.pone.0020069.g003
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PLoS ONE | www.plosone.org 5 May 2011 | Volume 6 | Issue 5 | e20069Figure 4. Cell exposure to compound JMN3-003 induces a temporary G1/S phase cell cycle arrest. A) FACS analysis of acridine orange-
stained HeLa cells incubated in the presence of JMN3-003 or hydroxyurea for 36 hours, or nocodazole for 16 hours. Dark grey shaded areas show
unstained cells, light grey areas correspond to vehicle-treated control cells, and areas under open black curves represent treated cell populations.
Dashed vertical lines indicate 2 N (G1/S) and 4N (G2/M) DNA contents. Data shown are representative of three experiments and reflect 10,000 events/
condition of treatment. B) Analysis of the phosphorylation status of cdc2-cyclin B kinase after cell exposure to JMN3-003 through immunoblotting
using specific antisera directed against phospho-cdc2 (Tyr15; a cdc2-P) or total cdc2 (a cdc2) for comparison. For control, cells were treated with
nocodazole, hydroxyurea, or alsterpaullone (right panel). Results shown are representative of multiple experiments. C) Wash-out of JMN3-003
restores cell proliferation. Growth rates of Vero cells were determined after 30-hour exposure of cells to JMN3-003 or vehicle only, followed by wash-
out of the substance. Values reflect cell divisions per day and are based on averages of six independent replicate experiments 6 SEM. D)G 1/S phase
cell cycle arrest does not affect MeV proliferation per se. Dose-response curves for alsterpaullone, a nanomolar CDK1/cyclin B kinase inhibitor, and
MeV-Alaska grown on Vero-Slam cell. Titers of cell-associated viral particles were determined 36 hours post-infection through TCID50 titration. JMN3-
003 was examined in parallel for comparison. Values reflect averages of three replicates 6 SD.
doi:10.1371/journal.pone.0020069.g004
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samples, indicating potent inhibition of viral replication. For
comparison, a concentration of 25 mM of the RdRp inhibitor AS-
136A, a nanomolar blocker of MeV replication [35], was required
to achieve comparable mRNA and antigenome reduction levels
(figure 7A).
When this assay was applied to orthomyxovirus infection, we
likewise observed a dose-dependent inhibition of influenza A/
WSN antigenome levels relative to vehicle treated controls
(figure 7B). Parallel quantification of genome copy numbers of
released progeny virus demonstrated that an approximate .100-
fold drop in relative viral antigenome levels correlates to a
.10,000-fold reduction in genome copies of released progeny
virions (figure 7B).
Assessment of viral RdRp activity in a plasmid-based mini-
replicon reporter system confirmed dose-dependent inhibition of
RdRp by JMN3-003 also in a sub-infection setting, since luciferase
reporter expression was fully blocked at compound concentrations
of approximately 100 nM (figure 7C). Taken together, these data
suggest indirect inhibition of the viral polymerase complex
through interaction of the compound with a cellular cofactor
required for RdRp activity as the basis for the antiviral effect of
JMN3-003.
JMN3-003 does not induce rapid emergence of viral
resistance
It has been suggested for different viral pathogens that a host-
directed antiviral approach has the potential to reduce the
frequency of viral escape from inhibition compared to direct
targeting of pathogen components [14,15]. To explore whether
resistance to JMN3-003 could be induced experimentally, we
attempted stepwise viral adaptation to growth in the presence of
Figure 5. Host cell mRNA synthesis and translation are unaffected by compound JMN3-003. A) Relative TaqMan RT-PCR-based
quantitation of three unstable cellular mRNAs (MCL1, ASB7, MKP-1) after exposure of cells to JMN3-003 for six hours. Controls were treated with
Actinomycine D (Act D) for comparison. CT values are expressed relative to vehicle-treated samples and reflect averages of three independent
experiments, each analyzed in triplicate, 6 SD. B–D) Expression of virus-encoded but not host cell or plasmid-encoded viral proteins is blocked by
JMN3-003. Immunodetection of transiently expressed MeV-F (B), virus-encoded MeV-F (C), and virus-encoded influenza A/WSN M2 (D) in cell lysates
after incubation of cells in the presence of compound or vehicle only (DMSO) for 30 hours. As internal cellular standard, membranes were probed for
GAPDH in parallel. Numbers correspond to average densitometric quantitations 6 SD of three experiments, representative immunoblots are shown.
(ND: not determined).
doi:10.1371/journal.pone.0020069.g005
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RdRp inhibitor AS-136A [36]. Following an escalating dose
scheme, inhibitor concentrations were doubled when virus-
induced cytopathicity became detectable microscopically. While
robust resistance to the pathogen-targeted AS-136A control
emerged rapidly in an approximate 15 to 20-day time window
(tolerated dose at the end of adaptation was $30 mM, equivalent
to $100-fold resistance), only marginal increases in the tolerated
dose could be detected for JMN3-003 after 90 days of continued
viral incubation in the presence of the substance (figure 8). These
results are consistent with a host-directed mechanism of action of
JMN3-003 and suggest the existence of a systemic barrier that
prevents rapid viral escape from inhibition by the article.
Discussion
In recent years, host cell-directed antivirals have experienced
growing recognition as a new concept for the development of
advanced generation antivirals with the potential to counteract the
challenge of preexisting or rapidly emerging viral resistance
[14,15]. Novel automated genomics and proteomics analyses have
greatly advanced our insight into host-pathogen interactions
[37,38,39,40,41,42,43,44]. These studies have underscored the
notion that several cellular pathways are exploited for virus
replication [45,46], supporting the hypothesis that a host-directed
antiviral may enjoy an expanded viral target range, rendering it
effective for the treatment of several related viral diseases.
Technologies applied for host-directed drug discovery include
cDNA and siRNA-based microarray analyses combined with
pathway-guided data mining [47,48,49,50,51], loss-of-function
screens using aptamers or small oligonucleotides [52,53,54,
55,56,57,58], protein array analyses [59] and chemical library
screening [60,61]. By combining automated library screening [19]
with counter screens against a variety of related viral pathogens of
the myxovirus families, we have identified a candidate scaffold
that, after moderate hit-to-lead chemistry, adheres to the profile of
Figure 6. In time-of-addition assays, JMN3-003 shows the inhibition profile of an RdRp blocker. A–B) Cell-to-cell fusion is unaffected by
the compound. Microphotographs of MeV-H and F expressing Vero-Slam cells (A) and quantitative cell-to-cell fusion assays (B) show membrane
fusion activities in the presence of JMN3-003 similar to those observed for vehicle (DMSO)-treated controls. The effect of fusion inhibitory peptide
(FIP) is shown in (B) for comparison. C) JMN3-003 antiviral activity is reversible and not based on cell priming. Vero-Slam cells were pre-treated with
1.0 mM JMN3-003 for 60 minutes, followed by compound wash-out and incubation for the indicated time periods; at t0, cells were infected with MeV-
Alaska. D) JMN3-003 lacks virucidal activity. MeV-Alaska particles were incubated with 1.0 mM JMN3-003 for 60 minutes, followed by dilution of
compound to 1.0 nM and infection of cells at an MOI of 0.033 in the presence of vehicle (JMN3-003/infect./DMSO). Equally treated controls received
vehicle only (DMSO/infect./DMSO), compound only after infection (DMSO/infect./JMN3-003), or compound for the duration of the experiment (JMN3-
003/infect./JMN3-003). E) Addition of JMN3-003 (1.0 mM final concentration) at the indicated times post-infection of cells with MeV-Alaska. For
comparison, inhibition profiles of the MeV entry inhibitor AS-48 (75 mM) and RdRp blocker AS-136A (25 mM) are shown. Controls received vehicle only
(DMSO) at the time of infection. For (C–E), values show titers of cell associated viral particles (TCID50/ml) and represent averages of at least three
experiments 6 SD.
doi:10.1371/journal.pone.0020069.g006
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antiviral activity is host cell species-dependent, indicating specific
interaction with a distinct host factor rather than a viral
component. Host cell-specific activity is incompatible with
compound docking to conserved viral factors. For example,
carbohydrate structures exposed on viral envelope glycoproteins
that are targeted by antiviral lectins such as pradimicin A [62].
Furthermore, it is incompatible with an undesirable unspecific,
promiscuous mode of action of the compound [63]; II) affinities
against a panel of human pathogens of the paramyxovirus family
as well as laboratory adapted and wild type influenza virus isolates
were very similar throughout (average EC50 concentrations are
,40 nM). Equivalent active concentrations argue against com-
pound docking to distinct viral components and suggest that
inhibition of distinct myxovirus families follows the same
mechanism of action; III) in vitro adaptation attempts to induce
viral resistance were unsuccessful even after extended exposure
times to the drug. A full assessment of the frequency of viral escape
from inhibition by JMN3-003 will certainly need to include in vivo
virus adaptation attempts in suitable animal models, since the rate
of resistance build-up may vary between tissue culture and in vivo
settings. We nevertheless reliably induced resistance in less than 30
days to a pathogen-directed MeV RdRp inhibitor that was
analyzed in parallel, which is fully consistent with our previous
experience [36] and provides confidence for the validity of our
overall experimental design for viral adaptation.
Mechanistic analysis of the bioactivity of the JMN3-003
compound class through characterization of exposed cells and
time-of-addition experiments revealed two distinct phenotypes, a
temporary cell cycle arrest in the G1/S phase and an arrest in the
myxovirus life cycle at a post-entry step. Current libraries of
chemical analogs of JMN3-003 do not yet permit a definitive
conclusion as to whether both activities adhere to discrete
structure-activity relationships or are causally linked, but a bulk
of experimental data demonstrate that host cell cycle arrest per se
has no inhibitory effect on replication of paramyxoviruses such as
MeV. Not only does the virus itself induce a G1/S-phase arrest in
infected T lymphocytes [29,30], we also found that exposure of
infected cells to alsterpaullone, a potent blocker of G1/S-phase cell
cycle progression through nanomolar inhibition of cellular cyclin-
dependent kinases [28], did not affect the extent of virus
replication even at concentrations exceeding reported alsterpaul-
lone EC50 values by more than 1,000-fold. Likewise consistent
Figure 7. Compound JMN3-003 inhibits viral RNA synthesis. A) Relative quantitations of MeV F mRNA and antigenome (+RNA) levels after
incubation of infected cells in the presence of compound for 40 hours. Samples were normalized for vehicle only (DMSO)-treated cells and DDCT
values calculated using cellular GAPDH as reference. Mock samples remained uninfected. Averages of three independent experiments, assessed in
triplicate each, 6 SD are shown. B) Quantitation of influenza A/WSN segment seven antigenome (+RNA) and of released progeny genomic RNA
(genome copies) after incubation of infected MDCK cells in the presence of compound for 24 hours. For +RNA quantitation, samples were normalized
and DDCT values calculated as outlined in (A). Released genome copies were quantified by TaqMan RT-PCR relative to an external standard, then
normalized for vehicle-treated controls. Averages of four experiments, assessed in triplicate each, 6 SD are shown. C) Luciferase reporter-based
assessment of viral RdRp activity in the presence of JMN3-003. BHK-T7 cells transfected with plasmids encoding the MeV minireplicon reporter system
were incubated in the presence of JMN3-003 or vehicle only for 36 hours. Values were normalized for luciferase activities found in vehicle (DMSO)-
treated controls and represent averages of three experiments assessed in duplicate each 6 SD.
doi:10.1371/journal.pone.0020069.g007
Figure 8. JMN3-003 prohibits rapid emergence of viral
resistance in vitro. MeV-Alaska remains sensitive to the compound
after continued adaptation events for a 90-day period, while resistance
(extensive viral CPE detectable in the presence of 30 mM compound) to
pathogen-directed AS-136A emerges in step-wise adaptations after 15–
25 days. Three independent adaptations (represented by solid, dotted
and dashed lines, respectively) were pursued for each compound.
doi:10.1371/journal.pone.0020069.g008
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on cell cycle arrest itself, virus inhibition was not restricted to the
context of immortalized, rapidly dividing tissue culture cell lines
but extended with equal potency to primary human PBMCs.
Reversible cell cycle arrest and block of virus replication
indicate non-covalent docking of JMN3-003 to its target structures,
which is corroborated by the compound’s stability, low chemical
reactivity profile and the complete absence of virucidal activity in
pre-incubation settings. An inhibition profile of JMN3-003 closely
mimicking that of AS-136A, the pathogen-directed blocker of
MeV RdRp targeting the viral L polymerase protein [36], and the
block in viral RdRp activity in the context of viral infection and
minireplicon reporter assays by JMN3-003 consistently point
towards interaction of the compound with a host cofactor essential
for RdRp function as the basis for its antiviral activity. While viral
RdRp depends on a variety of host cell components [1],
unperturbed cellular mRNA synthesis and, thus, uninterrupted
host RNA polymerase function in the presence of compound
exclude interference of JMN3-003 with essential transcription
initiation factors.
Recently, accumulating evidence has implicated host cell
kinases as regulators of the activity of RdRp complexes of different
negative-strand RNA viruses [64]: host cell kinases of the PI3K-
Akt pathway manipulate paramyxovirus RdRp activity through
Akt-mediated phosphorylation of the viral phosphoprotein, an
essential component of the RdRp complex. Furthermore, Akt
activity itself is upregulated through activation of PI3K during
influenza A infection via direct interaction of the viral NS1 protein
with PI3K [65,66]. In the case of MeV, however, published data
[67,68] and our own observations (Krumm and Plemper,
unpublished) demonstrate that Akt inhibition causes a moderate
reduction in virus release, whereas titers of cell-associated progeny
particles remain unchanged. While this rules out the PI3K-Akt
pathway as a direct target for JMN3-003, it illuminates the
intricate regulatory interactions between pathogen and host, which
provide a wealth of possible points of entry for antiviral
intervention. Future identification of the molecular target of
JMN3-003 carries high potential to further our understanding of
these interactions and may conceivably provide a basis for
pharmacophore extraction and structure-driven scaffold optimi-
zation.
We note that the central sulfur in the JMN3-003 chemical
scaffold could potentially render the molecule vulnerable to rapid
phase I oxidation and thus compromise both metabolic stability
and bioavailability. For instance, it has been reported that flavin-
containing monooxygenases [69], dioxygenases [70] and cyto-
chrome P-450 enzymes [71] catalyze oxidation of alkylaryl sulfides
to sulfoxides (R2S=O). However, the high stability of JMN3-003
in the presence of human hepatocyte subcellular fractions and
human plasma argues against an undesirable short in vivo half-life
of the substance. This is corroborated by good metabolic stability
of the structurally similar HIV reverse transcriptase inhibitor
RDEA-806 [72,73], which shares the central 2-thio-acetamide
connector with JMN3-003 and has achieved success in clinical
trials: the compound was well tolerated in both Phase 1 and 2a
studies after single or multiple oral doses and showed no drug-
related CNS toxicity [72,73], creating a clinical precedence for the
applicability of the broader scaffold. Although RDEA-806 follows
a different mechanism of action than JMN3-003 and lacks any
anti-paramyxovirus activity, the structural similarities provide
sufficient confidence for the overall developmental potential of the
JMN3-003 class to recommend it as a promising candidate for
advanced synthetic optimization towards preclinical validation
and development.
In toto, we have identified a novel chemical class of viral
inhibitors that block viral RdRp activity with a host factor-
mediated profile. A complete activity workup after synthetic
identification of a clinical lead analog will be required to fully
appreciate the range of the different viral families inhibited by the
substance. However, we consider human pathogens of the
myxovirus families that are primarily associated with acute disease
among the most suitable for host-directed antiviral efforts due to
anticipated short treatment regimens. While we cannot exclude
that resistance to JMN3-003 may eventually emerge in in vivo
settings, our in vitro adaptation efforts support the hypothesis that
the mechanism of action of this compound class establishes a
strong barrier against rapid viral escape from inhibition.
Materials and Methods
Cells and viruses
All cell lines were maintained at 37uC and 5% CO2 in
Dulbecco’s modified Eagle’s medium supplemented with 10%
fetal bovine serum. Vero (African green monkey kidney epithelial)
cells (ATCC CCL-81) stably expressing human signaling lympho-
cytic activation molecule (CD150w/SLAM), called in this study
Vero-SLAM cells [74], and baby hamster kidney (BHK-21) cells
stably expressing T7 polymerase (BSR-T7/5 (BHK-T7) cells [75])
were incubated at every third passage in the presence of G-418
(Geneticin) at a concentration of 100 mg/ml. Lipofectamine 2000
(Invitrogen) was used for cell transfections. Peripheral blood
mononuclear cells (PBMCs) were prepared through overlay of
whole blood samples from mixed, healthy human donors (Emory
University Institutional Review Board approval IRB00045690,
Phlebotomy of Healthy Adults for Research in Infectious Diseases
and Immunology) on Ficoll Hypaque solution, followed by
centrifugation at 2406g for 30 minutes at room temperature
and removal of the interphase material. Red blood cells were lysed
with RBC lysis solution (Sigma), followed by repeated washing of
extracted PBMCs with phosphate buffered saline and transfer to
tissue culture plates pre-coated with poly-L-lysine (Sigma). Other
primary human cell lines were obtained from PromoCell,
Germany. Virus strains used in this study were MeV isolate
MVi/Alaska.USA/16.00, genotype H2 (MeV-Alaska) [76],
HPIV3, MuV strain South Africa, RSV strain Long, laboratory
adapted influenza A strains WSN (H1N1) and PR8/34 (H1N1),
swine-origin influenza virus isolates S-OIV Texas and Mexico,
vaccinia virus and sindbis virus. To prepare virus stocks, cells
permissive for the virus to be amplified (Vero-Slam, Vero, HepG2
(ATCC HB-8065), and Madin-Darby canine kidney (MDCK))
were infected and incubated at 37uC. Cell-associated paramyxo-
virus and vaccinia virus particles were harvested by scraping cells
in OPTIMEM (Invitrogen), followed by release of virus through
two consecutive freeze-thaw cycles. Influenza virus and sindbis
virus particles were harvested from cell culture supernatants.
Titers of MeV and MuV were determined through 50% tissue
culture infective dose (TCID50) titration according to the
Spearman-Karber method [77] as described [78], titer of all other
viruses were determined by plaque assay on permissive cells.
Influenza A titration by TaqMan RT-PCR
To determine genome copy numbers of released progeny
influenza A particles (strains WSN, PR8/34, S-OIV Texas and
Mexico), culture supernatants of infected MDCK cells (4610
5
cells/well in a 12-well plate format) were harvested and total RNA
prepared using a QIAcube automated extractor and the QIAamp
viral RNA mini kit reagent. Purified RNA was then subjected to
quantitative real time (qRT) PCR analysis using an Applied
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TaqMan Fast Virus 1-Step Master Mix (Applied Biosystems).
Primers and probe are based on recent reports [79] and
universally reactive with all influenza A strains including the
recent S-OIV (H1N1) isolates. To generate a qRT-PCR standard,
genome segment seven of influenza A/WSN was subcloned into
pCR2.1-TOPO vector (Invitrogen) and copy numbers of the
resulting standard calculated using Promega’s BioMath Calculator
tools (http://www.promega.com/ biomath/). For each TaqMan
reaction, 10-fold serial dilutions of the linearized plasmid ranging
from 10
7 to 10
1 were amplified in parallel.
Compound synthesis
Chemical synthesis of compounds AS-48, AS-136A and RDEA-
806 was achieved as previously described [24,34,36]. Synthesis of
JMN3-003, N-(4-methoxyphenyl)-2-nitroaniline (substance (3) in
figure S1), and analogs JMN5-165 and JMN5-166 was achieved as
outlined schematically in figure S1. To prepare inhibitor stocks,
compounds were dissolved at 75 mM in DMSO.
Viral CPE-reduction assay
Vero-SLAM cells were infected with MeV-Alaska at an MOI of
0.4 pfu/cell in the presence of the inhibitor analyzed ranging from
75 mM to 293 nM in two-fold dilutions. At 96 hours post-infection,
cell monolayers were subjected to crystal violet staining (0.1% crystal
violet in 20% ethanol), and the absorbance of dried plates at 560 nm
determined. Virus-induced cytopathicity was then calculated accord-
i n gt ot h ef o r m u l a[ %r e l .C P E = 1 0 0 2(experimental-minimum)/
(maximum-minimum)*100], with minimum referring to infected,
vehicle-treated wells and maximum to mock-infected wells.
Virus yield reduction assay
Cells were infected with the specified myxovirus at an
MOI=0.1 pfu/cell (all paramyxoviruses assessed), 0.05 pfu/cells
(influenza viruses), 1.0 (vaccinia virus), or 10 sindbis virus) in the
presence of a range of compound concentrations or equivalent
volumes of solvent (DMSO) only, and incubated in the presence of
compound at 37uC. When vehicle treated controls approached the
end of the logarithmical growth phase, progeny viral particles were
harvested and titered by TCID50 titration, plaque assay or
TaqMan real-time PCR, respectively, as described above. Plotting
virus titers as a function of compound concentration allowed
quantitative assessment of resistance. Where applicable, 50%
inhibitory concentrations were calculated using the variable slope
(four parameters) non-linear regression-fitting algorithm embed-
ded in the Prism 5 software package (GraphPad Software).
Quantification of compound cytotoxicity
A non-radioactive cytotoxicity assay (CytoTox 96 Non-Radioactive
Cytotoxicity Assay, Promega) was employed to determine the
metabolic activity of cell after exposure to the compound. In a 96-
well plate format, 10,000 cells per well were incubated at 37uCf o r
24 hours in four replicates per concentration tested in the presence of
compound in two-fold dilutions starting at 75 mM. Substrate was then
added and color development measured at 490 nm using a BioRad
plate reader. Values were calculated according to the formula [%
toxicity=1002((experimental-background)/(maximum(vehicle treat-
ed)-background)*100)]. Values were plotted in dose-response curves
and, if applicable, CC50 concentrations calculated.
In vitro assessment of metabolic and plasma stability
JMN3-003 was mixed with liver S9 fractions (protein concen-
tration 2.5 mg/ml) from pooled mixed gender humans (Xeno-
Tech) at a final concentration of 1 mM and reactions initiated by
the addition of cofactors (1.14 mM NADPH, 1.43 mM glucose-6-
phosphate, 1.43 mM uridine 59-diphosphoglucuronic acid,
9.42 mM potassium chloride, 2.28 mM magnesium chloride) in
100 mM potassium phosphate buffer, pH 7.4. Samples were
incubated at 37uC with mixing, aliquots removed after 0, 15, 30
and 60 minutes and subjected to reversed-phase LC-MS/MS
(Applied Biosystems API 4000 QTRAP with heated nebulizer;
Turbo IonSpray for JMN5-166) analysis. Peak areas were
measured to calculate half life and percent of input compound
remaining according to the formulas t1/2=(20.693/slope of linear
regression analysis of log transformed peak area versus) and %
input remaining=(peak area of test compound at tx/peak area of
test compound at t0)*100. Positive controls to assess the metabolic
competency of the liver S9 fractions were 7-Ethoxycoumarin,
Propranolol, and Verapamil (Sigma), which were analyzed in
parallel to the article. To determine compound plasma stability,
articles were mixed with freshly prepared human plasma at a final
concentration of 0.5 mM and incubated at 37uC for up to
120 minutes. Aliquots were removed at distinct time points as
indicated and analyzed by LC-MS/MS with detection of the
compound at 254 nm. Values are expressed as percent of
compound remaining at each time relative to the amount of that
compound present at the starting time point.
Flow-cytometric analysis of cell cycle progression
Actively proliferating HeLa cells were exposed to JMN3-003
(10 mM), hydroxyurea (4 mM), or nocodazole (200 ng/ml) for
36 hours, followed by resuspension in buffer I (20 mM citrate/PO,
pH 3.0, 0.1 mM EDTA, 0.2 M Sucrose, 0.1% Triton X-100) and
staining in buffer II (10 mM Citrate/PO, pH 3.8, 0.1 M sodium
chloride, 20 mg/ml acridine orange) as described [80]. Green
fluorescence at 525 nm resulting from DNA intercalating acridine
orange was then measured using a BD LSRII flow cytometer and
FlowJo software (Tree Star) for data analysis. For comparison,
unstained and stained, solvent-only exposed cells were examined
in parallel.
SDS-PAGE and immunoblotting
Cells were lysed with RIPA buffer (50 mM Tris/CL, pH 7.2,
1% deoxycholate, 0.15% sodium dodecylsulfate, 150 mM sodium
chloride, 50 mM sodium fluoride, 10 mM EDTA, 1% NP-40,
1 mM PMSF, protease inhibitors). Aliquots with equal total
concentrations of cleared lysates (20,0006g; 10 min; 4uC) were
mixed with 2x-urea buffer (200 mM Tris, pH 6.8; 8 M urea; 5%
sodium dodecyl sulfate (SDS); 0.1 mM EDTA; 0.03% bromphe-
nol blue; 1.5% dithiothreitol) and denatured for 25 min at 50uC.
Samples were then fractionated on 10% SDS-polyacrylamide gels,
blotted to polyvinylidene difluoride (PVDF) membranes (Milli-
pore) and subjected to enhanced chemiluminescence detection
(Pierce) using specific antisera directed against phosphorylated or
non-phosphorylated cdc2-cyclin B kinase (Cell Signaling Tech-
nology), GAPDH (Abcam), the cytosolic tail of the MeV F protein
[81], or influenza A/WSN virus M2 (Thermo Scientific).
Immunostained PVDF membranes were developed using a
ChemiDoc XRS digital imaging system (Bio-Rad) and horseradish
peroxidase conjugated anti-species IgG (mouse or rabbit) antibod-
ies. For densitometry, signals were quantified using the Quanti-
tyOne software package (Bio-Rad).
Assessment of cell growth rates
Vero cells were seeded at a density of 6610
5 cells and incubated
in the presence of 10 mM JMN3-003 or vehicle only for 30 hours
at 37uC. Cells were then washed extensively and reseeded at a
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5 cells per well, followed by continued incubation
at 37uC and assessment of life/dead cell numbers every 24 hours
using a Countess automated cell counter (Invitrogen). Cells were
reseeded as before when fastest growing cultures approached
confluency. Growth rates were calculated for each 24-hour time
interval using the Prism software package (GraphPad Software
Inc.) based on the formula Y=Y0*exp(K*X) with Y equaling life
cell numbers, Y0 the Y value at the starting time (t0), and K the
growth constant equaling ln(2)/doubling-time.
Quantification of cellular and viral mRNA levels
Cells were infected with either recombinant MeV Edmonston
(recMeV-Edm) [82] (Vero cells, MOI=1.0) or influenza A/WSN
(MDCK cells, MOI=0.05), followed by removal of inocula one hour
post-infection and addition of JMN3-003 in growth media at 0.1 mM
or 1 mM. All MeV infected wells received in addition fusion
inhibitory peptide (FIP, Bachem) at 100 mM to prevent premature
breakdown of the monolayer through viral CPEin the vehicle control
wells prior to RNA extraction. Twenty-four (influenza A/WSN) or
forty (recMeV-Edm) hours post-infection, total RNA was prepared
from all wells using the QIAcube automated extractor and the
RNeasy Mini Kit (Qiagen), and subjected to reverse transcription
using Superscript II Reverse Transcriptase (Invitrogen). For RNA
samples originating from recMeV-Edm infected cells, antigenome-
specific primer 5-GGCTCCCTCTGGTTGT or oligo-dT primer
(viral mRNA and GAPDH quantification) were used for cDNA
priming. In the case of samples originating from influenza A/WSN
infected cells, primers for cDNA synthesis were 5-AGTAGAAA-
CAAGGTAGTTT (antigenome) or oligo-dT (mRNA and canine
GAPDH). Real-time reactions were carried out using an Applied
Biosystems 7500 Fast real-time PCR system and iQ Fast SYBR Green
Supermix with ROX (Bio-Rad). Probes were a fragment at the N/P
junction (MeV antigenomic RNA, 5-AACCAGGTCCACACAG
and 5-GTTG TCTGATATTTCTGAC), a fragment of MeV
F mRNA (5-GTCCACCATGGGTCTCAAGGTGAACGTCTC
and 5-CAGTTATTGAGGAGAGTT), a fragment of human
GAPDH (SABiosciences proprietary primers), a fragment of
influenza A/WSN segment seven (influenza A/WSN antigenomic
RNA, 5-tagctccagtgctggtct and 5-AAGGCCCTCCTTTCAGTCC),
and a fragment of canine GAPDH (Qiagen proprietary primer).
Melting curves were generated at the end of each reaction to verify
amplification of a single product. To calculate DDCT values, CT
values obtained for each sample were normalized for GAPDH as
reference and then DCT values of JMN3-003-treated samples
normalized for the FIP-treated controls. Final quantification was
based on three independent experiments in which each treatment
condition and RT primer setting were assessed in triplicate. To assess
the relative quantities of cellular mRNA, 9610
5 HeLa cells were
incubated in the presence of JMN3-003 (0.01, 0.1, 1.0, 10.0 mMf i n a l
concentration), AS-136A (25 mM), Actinomycine D (5 mg/ml), or
vehicle only for six hours at 37uC, followed by preparation of total
RNA as described above. Quantitative TaqMan RT-PCR was again
achieved using the TaqMan Fast Master Mix (Applied Biosystems)
combined with proprietary primer and probe sets specific for Induced
myeloid leukemia cell differentiation protein 1- (MCL1), MAPK
phosphatase 1 (MKP1), and ankyrin repeat and SOCS box-
containing protein 7- (ASB7) encoding mRNAs (Applied Biosystems).
Samples were standardized for GAPDH as before and normalized
values expressed relative to the equally analyzed vehicle-treated
controls.
Quantitative cell-to-cell fusion assays
An effector cell population (3610
5 cells/well) was cotransfected
with 2 mg each of MeV H and F expression plasmids. To inhibit
fusion until the cell overlay, the effector cells are incubated in the
presence of 100 mM fusion inhibitory peptide (Bachem). Single
transfections of plasmids encoding MeV F served as controls.
Target cells (6610
5 cells/well) were transfected with 4 mg of the
reporter plasmid encoding firefly luciferase under the control of
the T7 promoter. Two hours post-transfection, modified vaccinia
virus Ankara expressing T7 polymerase at an MOI of 1.0 PFU/
cell was added to the effector cells. Following incubation for 16 h
at 37uC, target cells were detached and overlaid on washed
effector cells at a 1:1 ratio and incubated at 37uC in the presence
of different JMN3-003 concentrations as indicated. Four hours
post-overlay, cells were lysed using Bright Glo lysis buffer
(Promega), and the luciferase activity determined in a lumines-
cence counter (PerkinElmer) after addition of Britelite substrate
(PerkinElmer). The instrument’s arbitrary values were analyzed by
subtracting the relative background provided by values of the
controls, and these values were normalized against the reference
constructs indicated in the figure legends. On average, background
values were ,1% of the values obtained for reference constructs.
For qualitative assessment, transfected Vero-SLAM cells were
photographed 18 hours post-transfection at a magnification of
6200.
Time of compound addition analysis
For virus pre-incubation assays, 10
7 infectious MeV-Alaska
particles were incubated for 60 minutes at 37uC in the presence of
JMN3-003 (1.0 mM final concentration) or vehicle only, followed by
1,000-fold dilution in growth media and transferred to 3610
5 Vero-
Slam cells/well (corresponding to final compound concentrations
after pre-incubation of 1 nM and an MOI=0.033). Reference wells
were kept at 1.0 mM JMN3-003 for the duration of the experiment.
Cell-associated viral particles were harvested 24 hours post-infection
and infectious titers determined by TCID50 titration. To assess cell
priming, Vero-Slam cells (3610
5/well) were incubated in the
presence of JMN3-003 at 1.0 mM for one hour at 37uCa tt h e
i n d i c a t e dt i m ep o i n t sp r e - i n f e c t i o n ,f o l l o w e db yw a s h i n ga n df u r t h e r
incubation in growth media. Immediately before infection, cells were
reseeded at a density of 2.5610
5 per well and infected with MeV-
Alaska at an MOI=0.2 pfu/cell. Inocula were replaced with growth
mediafour hours post-infection and cellsincubated for approximately
20 hours. Cell-associated viral particles were then harvested and
infectious titers determined by TCID50 titration. For post-infection
time-of-addition studies, 3610
5 Vero-Slam cells/well were infected
with MeV-Alaska as before, followed by addition of JMN3-003
(1.0 mM final concentration), entry inhibitor AS-48 (75 mM), or
RdRp inhibitor AS-136A (25 mM). Controls received vehicle only.
All wells were harvested 19 hours post-infection and titers of cell-
associated progeny virus determined by TCID50 titration.
Minireplicon assays
BSR T7/5 cells (5610
5/well) were transfected with plasmid
DNAs encoding MeV-L (0.24 mg), MeV-N (0.94 mg) or MeV-P
(0.29 mg) and 2 mg of the MeV luciferase minigenome reporter
plasmid [83]. Control wells included identical amounts of reporter
and helper plasmids but lacked the L-encoding plasmid. At the
time of transfection, JMN3-003 was added as specified, while
control wells received vehicle only for comparison. Thirty-six
hours post-transfection, cells were lysed with Bright GLO lysis
buffer and relative luciferase activities determined using the
Britelite substrate and a luminescence counter as outlined above.
In vitro virus adaptation
Adaptations were carried out essentially as we have previously
described [36]. Briefly, Vero-SLAM cells were infected with MeV-
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gradually increasing JMN3-003 concentrations starting at 0.5 mM.
Equally infected cells treated with the virus polymerase targeted
RdRp inhibitor AS-136A were examined in parallel. When
cultures became over confluent, cells were reseeded for continued
incubation in the presence of the same compound concentration
as before. At detection of extensive cell-to-cell fusion, cell-
associated viral particles were harvested, diluted 10-fold and used
for parallel infections of fresh cell monolayers in the presence of
compound at unchanged and doubled concentrations. Cultures
treated with the highest compound concentrations in which virus-
induced cytopathicity became detectable were used for further
adaptation. The approach was terminated after 90 days of
continued incubation or when virus-induced cytopathicity was
readily detectable in the presence of 30 mM compound in
accordance with previous results [36].
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